A cloud-based decision support solution for diagnostic and prognostication of prostate cancer

News - February 2017

Almi Invest provides seed funding to CADESS Medical AB.

Uppsala, Sweden – February 9, 2017 – CADESS Medical AB, a leader in digital pathology analytics for the diagnosis and prognostication of prostate cancer, today announced that Almi Invest has provided seed funding to CADESS Medical.

“Almi Invest’s decision to invest in CADESS Medical is an additional proof that CADESS’ patented technology is unique and has a large untapped commercial potential”, said Ingrid Carlbom, CTO and founder of CADESS Medical.

“CADESS Medical’s proprietary technology comprises a great platform to improve clinical outcome and health economy in prostate cancer diagnosis and prognostication. Together with the experienced team at CADESS Medical we are looking forward the development and realization of CADESS™ and digital pathology in general”, said Allan Asp, Investment Manager at Almi Invest.

The funding will be used to further speed up the development of CADESS™, its innovative and unique digital imaging solution consisting of sample preparation and staining protocols and algorithms that can recognize prostate cancer and determine the malignancy grade according to the Gleason grading system in minutes, and with an accuracy on par with the consensus scoring of 13 internationally well-renowned and experienced pathologists.

About Almi Invest

Almi Invest invests in companies which have scalable business ideas and potential to increase shareholder value long term. The companies shall be able to compete in Sweden as well as internationally and the customer need must be clearly identified and addressed. Almi Invest is looking for entrepreneurs and teams with the capability to build and develop successful growth companies. Almi Invest is the most active investor in growth companies in Sweden. Its portfolio consists of approximately 400 companies targeting a broad range of markets. Approximately 70 new investments are made every year. Its regional coverage enables Almi Invest to look for opportunities across the entire country. Almi Invest is a subsidiary of Almi Företagspartner AB. The fund structure includes eight regional venture capital management companies. For further information please see www.almi.se/Almi-Invest/.

About CADESS Medical AB

CADESS Medical AB is a Swedish medical analytics company offering CADESS™, a cloud-based innovative digital pathology decision support solution based on image analysis for diagnosis and prognostication of cancer intended to improve patient outcome and reduce healthcare costs for prostate cancer. CADESS is the result of ten years of research at the Centre for Image Analysis, Department of Information Technology at Uppsala University, in collaboration with Uppsala University Hospital. For more information see www.cadessmedical.com.


For Further information, please contact:

Ingrid Carlbom, Chief Technology Officer
Tel: +46 (0) 73 048 20 25
E-mail: ingrid.carlbom@cadessmedical.com

Johan von Heijne, Investor Relations and Executive Advisor
Tel: +46 705 95 15 10
E-mail: johan.vonheijne@cadessmedical.com